Zhaoke Ophthalmology Ltd. (HK:6622) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Zhaoke Ophthalmology Ltd. has announced the National Medical Products Administration’s approval of its Bimatoprost eye drop, a preservative-free treatment for glaucoma, marking it as China’s first single-dose bimatoprost eye drop without preservatives. The product aims to improve patient comfort and compliance by reducing the long-term side effects associated with preservatives found in other treatments. This development is particularly significant given the high prevalence of glaucoma in China, which accounts for about a quarter of the global patient population.
For further insights into HK:6622 stock, check out TipRanks’ Stock Analysis page.